1. Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.02% to 2% (vol/vol) oil, as measured 3 weeks after the 2nd and 3rd immunizations.
Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.02% to 2% (vol/vol) oil, as measured 3 weeks after the 2nd and 3rd immunizations. Each group consisted of 5 mice, and error bars represent the standard deviations of the means. Statistically significant differences (P < 0.05) were seen for the following groups: for postboost IgG1, all adjuvant groups (except the 0.02% and 0.1% SE groups) versus PfCelTOS alone, all GLA-SE groups versus SE groups at the same emulsion concentrations, 2% SE versus 0.02% or 0.1% SE, Montanide versus 0.02% to 2% SE, 0.02% or 0.1% GLA-SE versus GLA-AF, and GLA-AF versus 0.02% to 0.5% SE; for postboost IgG2a, all GLA-SE groups and 2% SE versus PfCelTOS alone, 0.02% or 0.1% GLA-SE versus SE at the same emulsion concentration, 2% SE versus 0.02% to 0.5% SE, all GLA-SE groups and 2% SE versus Montanide, and all GLA-SE groups (except the 0.5% group) and 2% SE versus GLA-AF; for post-2nd boost IgG1, all adjuvant groups (except the 0.02% SE group) versus PfCelTOS alone, 0.02% GLA-SE versus 0.02% SE, 2% SE versus 0.02% SE, Montanide versus all adjuvant groups except the 2% SE and 0.5% GLA-SE groups, and GLA-AF versus 0.02% SE; and for post-2nd boost IgG2a, all adjuvant groups (except the 0.02% to 0.5% SE groups) versus PfCelTOS alone, all GLA-SE groups versus SE groups at the same emulsion concentrations, 2% SE versus 0.02% to 0.5% SE, Montanide versus 0.02% to 2% SE, and GLA-AF versus 0.02% to 2% SE.
Christopher B. Fox et al. Clin. Vaccine Immunol. 2012; doi: /CVI